Loading...
01/10 17:15
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed outlook. Positive aspects include a 24% increase in net revenue and improved gross profit margins, alongside optimistic guidance for 2025. However, risks such as potential delays in CE Mark approval, competitive pressures, and partnership uncertainties with Mercy Health temper the overall sentiment. The Q&A reveals a lack of clarity on certain strategic integrations and commercial plans, adding to uncertainty. Given these factors, the stock is likely to experience a neutral movement in the next two weeks.
Net Revenue $6,300,000 (up 24% from $5,000,000) due to increased demand for Eversense three sixty five.
U.S. Revenue $4,500,000, contributing to overall net revenue growth.
Revenue Outside U.S. $1,800,000, contributing to overall net revenue growth.
Gross Profit $1,500,000 (up from $300,000) primarily driven by increased margins on the three sixty five day product and inclusion of previously expensed manufacturing costs.
Gross Profit Margin Approximately 18%, improved due to increased margins on the three sixty five day product.
Research and Development Expenses $7,300,000 (down $3,100,000 from the prior year) due to reduced clinical study spend and consultant costs.
Selling, General and Administrative Expenses $7,700,000 (down $400,000 from $8,100,000) due to favorable personnel costs, consulting fees, and legal expenses.
Net Loss $14,300,000 or $0.02 loss per share (down from $18,900,000 or $0.03 loss per share) due to improved gross profit margins and reduced R&D costs.
Cash and Cash Equivalents $64,600,000 as of 03/31/2025.
Debt and Accrued Interest $35,300,000, reduced from $55,700,000 after repaying $20,400,000 in convertible notes.
Common Stock Issued 30,400,000 shares from conversion of 12,000 shares of Series B preferred stock.
Proceeds from Sale of Common Stock Approximately $27,000,000, expected to extend cash runway into mid-2026.
Projected Gross Profit Margins for 2025 Expected to be between 25-30%.
Cash Utilization for 2025 Expected to be between $50,000,000 and $60,000,000.
Eversense 365 Integration: Integration with Sequel’s Twist automated insulin delivery system for real-time glucose monitoring and insulin delivery adjustments.
GEMINI Product Development: Development of a one-year sensor with built-in battery for continuous and optional swipe testing, expected IDE submission by year-end.
Freedom System Development: Development of a Bluetooth-enabled sensor designed to communicate directly with a user’s phone, eliminating the need for an on-body transmitter.
European Launch Planning: CE Mark application filed, with expected approval and launch in the second half of 2025.
U.S. Reimbursement Transition: Transitioning reimbursement from 180 to 365 days for Eversense, with many payers already covering the full year.
Revenue Growth: Net revenue grew 24% to $6.3 million in Q1 2025 compared to $5 million in Q1 2024.
Gross Profit Improvement: Gross profit increased to $1.5 million, driven by higher margins on Eversense 365.
Partnerships: Collaboration with Sweet Spot for virtual CGM monitoring and enhanced patient care.
Market Positioning: Focus on expanding Eversense 365 in key accounts and health systems to improve glycemic control and reduce diabetes complications.
Regulatory Issues: The company is awaiting the CE Mark approval for the Eversense three sixty five, which is crucial for the European launch planned for the second half of the year. Any delays in this approval could impact the launch timeline.
Supply Chain Challenges: The company is monitoring the evolving tariff situation, which could impact gross profit margins. Although they expect to mitigate negative impacts through operational changes, any unforeseen issues could affect costs.
Competitive Pressures: The company faces competition from other Continuous Glucose Monitoring (CGM) systems, particularly in the direct-to-consumer (DTC) market. Competitors are actively engaging in high-profile DTC efforts, which could affect market share.
Economic Factors: The company is experiencing seasonality in its business, which affects average selling prices (ASPs) and gross margins. Early-year patient assistance programs may reduce ASPs, impacting revenue.
Partnership Risks: The partnership with Mercy Health Systems is currently on hold due to their executive restructuring, which may delay the integration of Eversense with remote patient monitoring initiatives.
Reimbursement Transition Risks: The transition of U.S. reimbursement from the Eversense E3 to the Eversense three sixty five is ongoing, and any delays or issues in this process could impact revenue growth.
Eversense 365 Integration: Integration of Eversense 365 continuous glucose monitor with Sequel’s Twist automated insulin delivery system to enhance patient experience and simplify insulin delivery.
Collaboration with Sweet Spot: Partnership with Sweet Spot to enable virtual CGM monitoring for endocrinology practices, improving patient care and efficiency.
European Launch Planning: CE Mark application filed, with expectations for a European launch in the second half of 2025.
Pipeline Products: Development of GEMINI and Freedom systems, with IDE submission for GEMINI expected by year-end.
2025 Revenue Guidance: Full year 2025 global net revenue expected to be approximately $34 million to $38 million.
Gross Profit Margin: Projected gross profit margins to be between 25% and 30% for the full year 2025.
Patient Base Growth: Expecting to double the global patient base in 2025 compared to 2024.
Cash Utilization: Expected cash utilization between $50 million and $60 million in 2025.
Common Stock Sale Proceeds: In Q1, we received gross proceeds of approximately $27,000,000 from the sale of common stock by utilizing our at-the-market facility.
Debt Repayment: In January, the remaining outstanding 2025 convertible notes in the principal amount of $20,400,000 were repaid, reducing the total principal debt outstanding to $35,000,000.
Preferred Stock Conversion: In Q1, all preferred stock was converted into shares of common stock, with 12,000 shares of Series B preferred stock converted into about 30,400,000 shares of common stock.
The earnings call highlights strong financial performance with improved gross margins and reduced net loss. The company is expanding its market presence with product launches in Europe and increased DTC marketing spend. Despite some uncertainties in timelines and payer transitions, the guidance is optimistic with expected patient growth and revenue. Positive trends in patient acquisition and competitive dynamics further support a positive outlook. The Q&A section indicates management's confidence in growth opportunities, although some details were vague. Overall, the sentiment is positive, likely leading to a stock price increase of 2% to 8%.
The earnings call shows strong financial performance with a 37% increase in net revenue and improved gross profit margins. Despite a net loss, the company reduced R&D expenses and increased cash position through public offerings. The Q&A section highlights positive retention rates and potential growth from the consignment program and Eon Care. However, there are uncertainties in retention data for the 365 version and revenue impact from Eon Care. Overall, the financial results and strategic initiatives suggest a positive stock price movement in the short term.
The earnings call presents mixed signals. Strong points include the launch of Eversense 365, increased net revenue, and improved gross profit. However, concerns about regulatory issues, supply chain challenges, and competitive pressures balance these positives. The Q&A section reveals uncertainties about partnerships and integration timelines, further tempering optimism. Financial health is stable, but the lack of clear guidance and ongoing risks suggest a neutral outlook for the stock price over the next two weeks.
The earnings call presents a mixed outlook. Positive aspects include a 24% increase in net revenue and improved gross profit margins, alongside optimistic guidance for 2025. However, risks such as potential delays in CE Mark approval, competitive pressures, and partnership uncertainties with Mercy Health temper the overall sentiment. The Q&A reveals a lack of clarity on certain strategic integrations and commercial plans, adding to uncertainty. Given these factors, the stock is likely to experience a neutral movement in the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
